Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy

Please, find the full article “Discovery and Development of ANV419, an IL-2/Anti-IL-2 Antibody Fusion Protein with Potent CD8+ T and Natural Killer Cell-Stimulating Capacity for Cancer Immunotherapy.” mAbs 16 (1). doi:10.1080/19420862.2024.2381891, authors: Murer, Patrizia, Barbara Brannetti, Jean-Michel Rondeau, Laetitia Petersen, Nicole Egli, Simone Popp, Catherine…
Read more

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

— ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential — Basel, 29 May 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug…
Read more

Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of Cancer

— ANV419 delivers high dose IL-2 to patients with a good safety and tolerability profile —
Basel, December 14, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced the publication of updated clinical data from the ongoing Phase I study of ANV419…
Read more

Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors

— ANV600 is a potent, cis-signaling, IL-2Rβ/γ agonist which efficiently expands intratumoral stem-like CD8+ T cells —
Basel, November 1, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the 38th Annual Meeting…
Read more

Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting

— ANV419 243 µg/kg selected as recommended Phase 2 dose for solid tumors —
Basel, October 16, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on its lead program ANV419 at the European Society of…
Read more

Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting

Basel, June 3, 2023 – OMNIA-1, a Phase I/II study of ANV419, an IL- 2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma (download poster here).
Read more

Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting.

Basel, April 18, 2023 – Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting (download poster here).
Read more

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting

— ANV600 is a potent, cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells — Basel, March 23, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for Cancer…
Read more

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma

— OMNIA-1 is a Phase I/II study to determine the efficacy of ANV419 as monotherapy and in combination with anti-PD1 or anti-CTLA4 antibodies in advanced melanoma —
Basel, February 2, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced the first patient…
Read more

Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting

— ANV419 delivers high dose IL-2 to patients with good safety and tolerability — — Deepening of tumor response with continued ANV419 —
Basel, November 10, 2022 – Anaveon, a clinical stage, immuno-oncology company, today announced updated clinical data from the ongoing Phase…
Read more

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

— ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity —
— A Phase II program of ANV419 has been initiated in Melanoma and multiple combination trials, including in Multiple Myeloma, are in preparation…
Read more

Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO Congress 2022

Basel, July 29, 2022 – Anaveon today announced that it will present new clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new preclinical data further elucidating the mode of action of this powerful and selective…
Read more

Anaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419

Basel, June 9, 2022 – Anaveon, a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND application for ANV419-101, a Phase I/II mono treatment dose confirmation and combination dose-finding, global study, in patients with advanced cutaneous melanoma.…
Read more

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

— ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity — — A Phase II program of ANV419 has been initiated in multiple tumor types, including melanoma, alongside multiple combination trials — Basel, April 8, 2022 – Anaveon,…
Read more

Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022

Basel, March 9, 2022 – Anaveon, a clinical-stage immuno-oncology company, today announced that it will present first clinical data from the ongoing Phase I/II study of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, in a poster presentation at the…
Read more

Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting

— ANV419 demonstrates highly promising safety profile —
Basel, November 12, 2021 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on its lead program ANV419 at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting…
Read more

Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

— ANV419 is a powerful and selective interleukin-2 (IL-2) agonist targeting cancer —
Basel, June 24, 2021 – Anaveon, a clinical stage, immuno-oncology company, today announced that it has successfully dosed the first patient in a Phase I/II open label study of ANV419,…
Read more

Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

— ANV419 is a powerful and selective interleukin-2 (IL-2) agonist targeting cancer —
Basel, March 25, 2021 – Anaveon, a clinical stage, immuno-oncology company, today announced that its Clinical Trial Application (CTA) has been accepted by the Spanish Agency of Medicines and Medical…
Read more

Anaveon announces presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

— ANV419 is a unique approach to no-alpha IL-2 agonists by taking advantage of a highly selective antibody which binds the same site as the alpha receptor and is able to completely abolish its binding —
Basel, November 10, 2020 – Anaveon, an…
Read more